Study of IBI362 for sleep apnea with obesity
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a sleep study (polysomnography) showing at least 15 breathing pauses per hour (AHI ≥15).
- Your body mass index (BMI) must be 28 or higher.
- If you use a PAP machine, you must have used it consistently for at least 3 months and agree to continue, but stop it for up to 7 days before certain tests.
- If you don't use a PAP machine, you cannot have used one for at least 4 weeks before the study.
- You cannot have type 1 or type 2 diabetes, or have had recent weight loss surgery or certain other treatments for sleep apnea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IBI362 for people with heart failure and obesity. The medicine may help improve symptoms and quality of life. You must have a specific type of heart failure (HFpEF or HFmrEF) and a BMI of 28 or higher.
This study tests an injectable medicine (IBI362) to see if it helps lower blood pressure in people who are overweight or have obesity. You may be eligible if you have high blood pressure but are not currently taking medication for it, and you do not have diabetes or major heart problems.
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
This trial tests an investigational drug called XW003 to see if it helps people with obesity and obstructive sleep apnea who are already using a positive airway pressure (PAP) machine, like CPAP. It aims to improve weight loss and sleep apnea symptoms.
This study tests a new injectable medicine (NNC0487-0111) to help people lose weight and improve obstructive sleep apnea (a breathing condition during sleep). You must already be using a CPAP machine (positive airway pressure device) for your sleep apnea.
Hear when a new Sleep Apnea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.